Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arsenic trioxide Clear all
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer

NCT00005999
View directory record Official record
Conditions
Cervical Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT00551460
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide, gemtuzumab ozogamicin, mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
192
States / cities
Roseville, California • Sacramento, California • Stanford, California + 139 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

NCT00250042
View directory record Official record
Conditions
Leukemia, Other, Cancer
Interventions
Gleevec and Arsenic Trioxide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

NCT00004149
View directory record Official record
Conditions
Prostate Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Up to 120 Years · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas

NCT00095771
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
3 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 21, 2026, 9:05 PM EDT
Withdrawn Phase 2 Interventional

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00085345
View directory record Official record
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy
Drug · Procedure
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Glendale, Arizona • Bakersfield, California • Campbell, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Withdrawn Phase 1 Interventional

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

NCT00504101
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Arsenic trioxide, Bortezomib, Melphalan, Autologous hematopoietic stem cell transplantation
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

NCT00621023
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Arsenic Trioxide and Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NCT02312037
View directory record Official record
Conditions
CD33 Positive Acute Myelogenous Leukemia
Interventions
Antibody Drug Conjugate Chemotherapeutic
Biological
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
142
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

NCT00005595
View directory record Official record
Conditions
Lymphoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

NCT01404949
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
Tretinoin and Arsenic Trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 1 Interventional Results available

Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03318016
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Cyclophosphamide 500 MG, Cyclophosphamide 1000 MG, Cyclophosphamide 2000 MG, Cyclophosphamide 3000 MG, Cyclophosphamide 4000 MG
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

NCT00195104
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Arsenic Trioxide (Tricenox), Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

NCT00201695
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Doxil®, Vincristine, Dexamethasone, Arsenic Trioxide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

NCT00053222
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma

NCT00005040
View directory record Official record
Conditions
Lymphoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

NCT00104806
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cholecalciferol, arsenic trioxide
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT00081133
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide, imatinib mesylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 9:05 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide in Treating Patients With Advanced Solid Tumors

NCT00003630
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

NCT00017069
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
arsenic trioxide, dexamethasone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 21, 2026, 9:05 PM EDT
Terminated Phase 3 Interventional Results available

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

NCT00513305
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Arsenic trioxide, Low-dose cytarabine alone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
60 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 21, 2026, 9:05 PM EDT